TaiGen Biopharmaceuticals Holdings Limited Stock
Equities
4157
KYG866171005
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
15.05 TWD | -1.63% | +0.33% | -0.99% |
Sales 2022 | 36.23M 1.12M | Sales 2023 | 123M 3.8M | Capitalization | 10.91B 337M |
---|---|---|---|---|---|
Net income 2022 | -237M -7.31M | Net income 2023 | 137M 4.23M | EV / Sales 2022 | 294 x |
Net cash position 2022 | 860M 26.55M | Net cash position 2023 | 963M 29.73M | EV / Sales 2023 | 80.8 x |
P/E ratio 2022 |
-48.5
x | P/E ratio 2023 |
80
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 50% |
1 day | -1.63% | ||
1 week | +0.33% | ||
Current month | -1.95% | ||
1 month | +0.67% | ||
3 months | +0.67% | ||
6 months | -0.66% | ||
Current year | -0.99% |
Managers | Title | Age | Since |
---|---|---|---|
Philip Huang
CEO | Chief Executive Officer | - | 18-12-16 |
Richard Lue
DFI | Director of Finance/CFO | - | 16-03-31 |
Ming-Chu Hsu
BRD | Director/Board Member | - | 01-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shou-Chuan Ho
BRD | Director/Board Member | - | 13-04-28 |
Hong Jen Chang
BRD | Director/Board Member | 68 | 13-03-31 |
Sheng Fu Yu
BRD | Director/Board Member | 79 | 19-06-11 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 4 M€ | -4.41% | - | |
0.00% | 34 M€ | +3.77% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-12 | 15.05 | -1.63% | 1 757 044 |
24-05-10 | 15.3 | -0.33% | 1,313,513 |
24-05-09 | 15.35 | +2.68% | 3,175,523 |
24-05-08 | 14.95 | +0.67% | 699,175 |
24-05-07 | 14.85 | -0.67% | 1,576,230 |
End-of-day quote Taipei Exchange, May 12, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
-0.99% | 338M | |
+5.03% | 109B | |
+10.83% | 105B | |
-0.38% | 22.25B | |
-12.31% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-9.07% | 16.85B | |
+4.60% | 13.76B | |
+34.81% | 12.46B |
- Stock Market
- Equities
- 4157 Stock